NRF2 is a master regulator of oxidative stress response. SCO-116 is an oral NRF2 activator that protects cells from oxidative stress due to inflammation and injury. In preclinical studies, SCO-116 activated NRF2 in the kidney and the liver and suppressed the progression of chronic kidney disease and NASH. Currently, we are carrying out nonclinical safety studies for the conduct of human clinical trials.

Indication

  • Chronic kidney disease (CKD)
  • Diabetic kidney disease (DKD)
  • Nonalcoholic steatohepatitis (NASH)
  • Other oxidative stress-related diseases
  • Antioxidant effect
SCO-116
Cytoplasm
KEAP1
NRF2

KEAP1-NRF2
interaction
inhibition

Nucleus

NRF2 activation

NASH

肝臓

Anti-fibrosis
Anti-fatty liver

CKD/DKD

腎臓

GFR increase
Anti-fibrosis

Other oxidative stress
related diseases

Oxidative stress is cytotoxic and causes various diseases including CKD/DKD and NASH. NRF2 is a transcription factor that protects cells from oxidative stress. NRF2 binds to KEAP1 and is degraded by the ubiquitin-proteasome pathway. SCO-116 inhibits NRF2 degradation by binding to KEAP1 and activates NRF2 (KEAP1-NRF2 interaction inhibitor). As a result, SCO-116 induces expression of various endogenous antioxidant molecules and reduces oxidative stress that causes various diseases.